Title:

96 AUD million investment puts Connect MPID in the head of RNA research

Date:
05 October 2023
First image:
Render of the entrance
Text:

IASP member Macquarie Park (Australia) plans to construct a first-of-its-kind research facility. With a 96 AUD million investment, the park plans an RNA research and manufacturing space, managed by Myeloid Therapeutics, to be built on the University campus starting in 2024.

Ribonucleic acid (RNA) therapies are becoming increasingly popular in medical technologies and services, focusing on cancer and rare genetic diseases. The treatments have improved patient outcomes – the acid is responsible in modifying the “instructions” held in the DNA of the human genome into functional proteins.

This project will stimulate the R&D and biotech innovation community in New South Wales and help Australia become a global leader in RNA research, with the facility being built in Macquarie’s “ecosystem of health”, joining other industry-related organisations including Macquarie University teaching hospital, AstraZeneca, and Johnson & Johnson.

“Our world-leading researchers and clinicians are engaged in answering some of the most urgent medical questions of our time, working to improve diagnosis and treatments for Alzheimer’s disease, motor neurone disease and cancers - all areas where RNA research has tremendous potential” said Macquarie University President and Vice-Chancellor, Bruce Dowton. Expected to be finished by 2025, the construction of the RNA lab will bring over 200 jobs in the short and long term, which will bring support to the local community and talent pool.

Youtube video html:
Tags: